Advertisement
Screener

CRISPR THERAPEUTICS AG (CRSP) Foreign Currency Transaction Gain (Loss), Unrealized

2.3 / 5 stars · 44/94 Roast Me

CRISPR THERAPEUTICS AG Foreign Currency Transaction Gain (Loss), Unrealized

CRISPR THERAPEUTICS AG (CRSP) reported Foreign Currency Transaction Gain (Loss), Unrealized of $9.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-02-25.

Discontinued › Cash Flow › Operating Activities

us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2019-02-25

  • CRISPR THERAPEUTICS AG foreign currency transaction gain (loss), unrealized for the quarter ending 2017-12-31 was $0.00.
  • CRISPR THERAPEUTICS AG foreign currency transaction gain (loss), unrealized for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
  • CRISPR THERAPEUTICS AG foreign currency transaction gain (loss), unrealized for the quarter ending 2017-06-30 was $10.00K.
  • CRISPR THERAPEUTICS AG foreign currency transaction gain (loss), unrealized for the quarter ending 2017-03-31 was -$1.00K.
  • CRISPR THERAPEUTICS AG foreign currency transaction gain (loss), unrealized for fiscal 2017 was $9.00K.
  • CRISPR THERAPEUTICS AG foreign currency transaction gain (loss), unrealized for fiscal 2016 was -$2.00K, a 110.00% decline from fiscal 2015.
  • CRISPR THERAPEUTICS AG foreign currency transaction gain (loss), unrealized for fiscal 2015 was $20.00K, a 92.31% decline from fiscal 2014.
  • CRISPR THERAPEUTICS AG foreign currency transaction gain (loss), unrealized for fiscal 2014 was $260.00K.
Period endForeign Currency Transaction Gain (Loss), Unrealized 3 monthForeign Currency Transaction Gain (Loss), Unrealized 6 monthForeign Currency Transaction Gain (Loss), Unrealized 9 monthForeign Currency Transaction Gain (Loss), Unrealized 12 month
2017-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25
$0.00
derived: sum of 2 quarters · filed 2019-02-25
$10.00K
derived: sum of 3 quarters · filed 2019-02-25
$9.00K
10-K · filed 2019-02-25
2017-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
$10.00K
derived: sum of 2 quarters · filed 2018-11-07
$9.00K
10-Q · filed 2018-11-07
$0.00
derived: sum of 4 quarters · filed 2019-02-25
2017-06-30$10.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
$9.00K
10-Q · filed 2018-08-07
$0.00
derived: sum of 3 quarters · filed 2019-02-25
$21.00K
derived: sum of 4 quarters · filed 2019-02-25
2017-03-31-$1.00K
10-Q · filed 2018-05-08
-$10.00K
derived: sum of 2 quarters · filed 2019-02-25
$11.00K
derived: sum of 3 quarters · filed 2019-02-25
$8.00K
derived: sum of 4 quarters · filed 2019-02-25
2016-12-31-$9.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25
$12.00K
derived: sum of 2 quarters · filed 2019-02-25
$9.00K
derived: sum of 3 quarters · filed 2019-02-25
-$2.00K
10-K · filed 2019-02-25
2016-09-30$21.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
$18.00K
derived: sum of 2 quarters · filed 2017-11-08
$7.00K
10-Q · filed 2017-11-08
-$72.00K
derived: sum of 4 quarters · filed 2018-03-08
2016-06-30-$3.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10
-$14.00K
10-Q · filed 2017-08-10
-$93.00K
derived: sum of 3 quarters · filed 2018-03-08
2016-03-31-$11.00K
10-Q · filed 2017-05-11
-$90.00K
derived: sum of 2 quarters · filed 2018-03-08
2015-12-31-$79.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08
$20.00K
10-K · filed 2018-03-08
2015-09-30$99.00K
10-Q · filed 2016-11-22
2014-12-31$260.00K
10-K · filed 2017-03-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Greenland Mines Ltd (GRML)United States$2.362B